SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as investors debate the sustainability of the AI infrastructure cycle, with community sentiment split between those viewing the stock as a long-term leader amid rumors of product delays and those frustrated by its recent underperformance compared to other semiconductor peers. While management continues to reiterate that its AI product roadmap remains intact, market participants are actively monitoring the stock for signs of institutional accumulation versus potential capitulation during a broader rotation in tech sector leadership.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is seeing significant investor attention following an unexpected Q2 delivery beat and an upward revision to its full-year vehicle delivery guidance. The community is actively debating the stock's potential for a short squeeze and long-term scaling, with bulls highlighting the R2 model as a key volume driver while bears remain focused on persistent dilution concerns and the company's path to profitability.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is currently trending due to positive Phase 3 trial data for its COMP360 therapy, which demonstrates durable therapeutic benefits and a strong safety profile. Investors are actively discussing the company's regulatory momentum following FDA support for a rolling NDA submission, while clinical milestone catalysts and potential for breakthrough treatment in depression continue to drive community enthusiasm.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened community engagement driven by intense short interest of over 40% and significant call option activity, leading many investors to monitor the stock for a potential squeeze. While some traders are focused on technical resistance levels and recent merger updates as potential catalysts, others remain cautious of the stock's volatility and historical price patterns.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate the company's transition into an enterprise-wide agentic AI orchestration layer, with community sentiment deeply split between those highlighting the massive short interest as a potential squeeze catalyst and skeptics focused on persistent price stagnation. Bulls are pointing to the company's GAAP profitability and cash-rich balance sheet as reasons to buy the dip, while others express frustration over the stock's inability to sustain momentum despite positive fundamental developments.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following a transformative deal with Anthropic, featuring a 20-year data center lease expected to generate significant long-term revenue. While the stock has seen volatile price action, the community is heavily debating the company's shift from a Bitcoin mining focus to a core AI infrastructure provider, with many investors maintaining bullish long-term sentiment despite recent short-term market fluctuations.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The firm's product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is experiencing intense market activity following a ten-billion-dollar acquisition agreement by Vertex Pharmaceuticals, a move that provides a significant premium to shareholders. The community is actively celebrating the buyout while discussing the potential for a sector-wide rotation into similar biotech growth plays and debating whether to hold positions or rotate capital.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is trending as investors focus on its recently secured U.S. patent for edge-native AI autonomy and its strategic inclusion in Department of War exercises like Northern Strike 26-2. Community discussion is heavily centered on the company's SwarmOS and Gremlin-X technology as a potential disruptor in autonomous defense systems, with many participants actively debating its long-term potential as a defense prime versus the impact of ongoing short interest.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is currently trending as investors focus on its strategic manufacturing joint venture with Toyota, which aims to scale production for its electric air taxi aircraft. While the community remains divided between long-term believers in Joby's FAA certification progress and skeptics betting against the stock due to volatility, retail traders are actively debating its market positioning relative to competitors in the eVTOL space.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is currently seeing heightened investor interest driven by a significant price target hike from Goldman Sachs and strategic partnerships, including new collaborations in autonomous driving. While the broader semiconductor sector remains volatile due to concerns over AI-cycle sustainability, the community remains actively divided between bullish sentiment regarding the company's data center and AI compute roadmap and bearish concerns about stretched valuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?

Key PointsKyverna Therapeutics is a clinical-stage biopharmaceutical firm advancing cell therapies for autoimmune diseases...

Kyverna Therapeutics Names Greg Martini CFO

(RTTNews) - Kyverna Therapeutics, Inc. (KYTX), Monday announced the appointment of Greg Martini as Chief Financial Officer, effective May 18...

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have received an average rating of 'Moderate Buy' from the five research firms that are covering the company, Marketbeat Ratings...

Kyverna Therapeutics (KYTX) to Release Earnings on Tuesday

Kyverna Therapeutics (NASDAQ:KYTX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

AIGH Capital Management LLC Acquires Shares of 1,500,000 Kyverna Therapeutics, Inc. $KYTX

AIGH Capital Management LLC purchased a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,500,000 shares of the company's stock, valued at approximately...

Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA

Kyverna Therapeutics (NASDAQ:KYTX) highlighted new clinical data for its CD19-directed autologous CAR T-cell therapy mivocabtagene autoleucel (miv-cel), formerly KYV-101, during an American Academy of Neurology (AAN) conference call focused on stiff person syndrome (SPS) and generalized myasthenia g...

Peapod Lane Capital LLC Decreases Holdings in Kyverna Therapeutics, Inc. $KYTX

Peapod Lane Capital LLC decreased its position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 42.3% during the 4th quarter, according to its most recent disclosure with the SEC. The...

Kyverna Therapeutics' (KYTX) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Kyverna Therapeutics in a research note on Thursday...

Kyverna Therapeutics (NASDAQ:KYTX) Shares Gap Up   - Should You Buy?

Kyverna Therapeutics (NASDAQ:KYTX) Shares Gap Up - Should You Buy...

Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP.read more...

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.68	--	--	N/A
Q1 '26	-$0.75	-$0.66	12.20%	BEAT
Q4 '25	-$0.85	-$0.80	5.99%	BEAT
Q3 '25	-$0.97	-$0.85	12.47%	BEAT
Q2 '25	-$1.04	-$0.97	7.08%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

KYTXKyverna Therapeutics Inc.

Upcoming Earnings: Q2 '26

Historical Earnings

Latest KYTX News